Small Molecules

05 May 2017 Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor
05 May 2017 GENFIT: First patient enrolled in a phase 2 trial recruiting adults with Primary Biliary Cholangitis (PBC), a rare liver disease
04 May 2017 OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial
04 May 2017 ContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex (TXL™) for Treatment of Hepatitis B Virus (HBV)
04 May 2017 BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acne
04 May 2017 Poxel Announces Positive Top Line Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes
03 May 2017 Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
03 May 2017 Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis
03 May 2017 Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata
03 May 2017 Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis
03 May 2017 Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
02 May 2017 Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038
02 May 2017 Otsuka and Lundbeck Announce Results of Brexpiprazole on Symptoms of Agitation Related to Alzheimer’s-Type Dementia
02 May 2017 Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia
02 May 2017 Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery
02 May 2017 NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease
02 May 2017 Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML
29 Apr 2017 Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection
29 Apr 2017 Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
29 Apr 2017 Takeda Announces FDA Accelerated Approval of ALUNBRIGTM (brigatinib)
29 Apr 2017 Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA Based on EINSTEIN CHOICE Data, Which Showed Superiority with XARELTO® (rivaroxaban) Versus Aspirin in Reducing Risk of Recurrent Venous Thromboembolism (VTE), with Low Ra
28 Apr 2017 Investigational Cladribine Tablets Data Show Greater Treatment Effect in Relapsing MS Patients at a Higher Risk of Disease Progression
28 Apr 2017 Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
28 Apr 2017 Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating significant anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options
28 Apr 2017 Sage Therapeutics Announces Initiation of Phase 1 Development and First Dosing of SAGE-718

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing